Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 22 August 2012 | By Alexander Gaffney, RAC
Indian generic drug manufacturer Ranbaxy announced 22 January that the US Food and Drug Administration (FDA) has, per its request, withdrawn 27 Abbreviated New Drug Applications (ANDAs) for products as part of a Consent Decree signed in January.
The Consent Decree, more formally known as a Consent Decree of Permanent Injunction, was the end result of an investigation by FDA into data integrity deficiencies at a number of the company's India- and US-based manufacturing facilities. The company signed onto the decree in January and shortly thereafter received approval from the US Department of Justice.
As part of the decree, FDA said the company would be required to permanently withdraw ANDAs for products originating from its facility in Batamandi, India.
"Corporate Defendants shall withdraw all NDAs and ANDAs that contain data or other information generated or developed at Batamandi, and shall never submit another Application to FDA for any drug that is the subject of the withdrawn Batamandi NDAs and ANDAs and shall never transfer such NDAs and ANDAs to a third party," wrote DOJ in the decree.
At the time of the decree, DOJ officials said the company had, "Submitted false data in drug applications to the FDA, including the backdating of tests and the submitting of test data for which no test samples existed … making many of Ranbaxy's drugs adulterated, potentially unsafe and illegal to sell in the US."
In a 22 August statement, Ranbaxy said the products had already been discontinued-FDA has prevented products manufactured at the facility from entering the US since 2008-and would have a, "Negligible impact on the company's business."
Tags: Consent Decree, Generic, ANDA, Ranbaxy, Latest News
Regulatory Focus newsletters
All the biggest regulatory news and happenings.